Document Detail


Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients.
MedLine Citation:
PMID:  8997549     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have conducted a preliminary study of the optimum conditions for a therapeutic effect of ganglioside GM1 in Alzheimer's disease. Five patients with the early onset form of Alzheimer's disease (AD type I) received the ganglioside by intracerebroventricular administration for 12 months. Bilateral stereotactic punction of the frontal horns of the ventricular system was performed, and shunt catheters were implanted and connected to a programmable pump. The optimum GM1 dose varied between 20 and 30 mg/24 h. Neurological neuropsychological, psychiatric and neurochemical examinations were performed 7 days before surgery and on days 30, 90, 180 and 360. No patient found the surgery difficult and no patient or relative regretted that they participated in the study. The patients became more active and safer in relation to others and to performance of various activities from day 90. The cerebrospinal fluid level of the monoamine metabolites homovanillic acid and 5-hydroxyindoleacetic acid and the neuropeptide somatostatin increased.
Authors:
L E Augustinsson; K Blennow; C Blomstrand; G Bråne; R Ekman; P Fredman; I Karlsson; M Kihlgren; W Lehmann; A Lekman; J E Månsson; I Ramström; A Wallin; C Wikkelsö; C G Gottfries; L Svennerholm
Related Documents :
631899 - The prevalence of ay and ad subtypes of the hepatitis b surface antigen in belgium.
16681429 - Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic...
19352589 - Negative effects of anemia on quality of life and its improvement by complete correctio...
20491609 - Effect of brain-derived neurotrophic factor val66met polymorphism and serum levels on t...
2683619 - Clinical experience with and side-effects of tacrine hydrochloride in alzheimer's disea...
11252529 - Baroreflex sensitivity determined by spectral method and heart rate variability, and tw...
19787469 - The effects of cachexia and related components on pulmonary functions in patients with ...
20968199 - Evolution of chronic hypertensive nephropathies treated with ace inhibitors on patients...
24290849 - Loss of motor unit size and quadriceps strength over 10years in post-polio syndrome.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Dementia and geriatric cognitive disorders     Volume:  8     ISSN:  1420-8008     ISO Abbreviation:  Dement Geriatr Cogn Disord     Publication Date:    1997 Jan-Feb
Date Detail:
Created Date:  1997-04-09     Completed Date:  1997-04-09     Revised Date:  2008-03-24    
Medline Journal Info:
Nlm Unique ID:  9705200     Medline TA:  Dement Geriatr Cogn Disord     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  26-33     Citation Subset:  IM    
Affiliation:
Department of Clinical Neuroscience, Göteborg University, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Alzheimer Disease / drug therapy*,  physiopathology,  psychology
Cerebrovascular Circulation / physiology
Dose-Response Relationship, Drug
Female
G(M1) Ganglioside / adverse effects,  therapeutic use*
Humans
Injections, Intraventricular
Male
Middle Aged
Neuropsychological Tests
Chemical
Reg. No./Substance:
37758-47-7/G(M1) Ganglioside

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Age vs. aging in the pathogenesis of senile dementia of the Alzheimer type: electrophysiological evi...
Next Document:  Neurochemical differences in the CSF between Binswanger's and Alzheimer's disease.